The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis.

@article{Ahluwalia2015TheGE,
  title={The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis.},
  author={Manmeet S. Ahluwalia and Laura Butcher and H Donovan and Clare L. Killick-Cole and Paul M. Jones and Jorge D. Erusalimsky},
  journal={Journal of thrombosis and haemostasis : JTH},
  year={2015},
  volume={13 6},
  pages={
          1103-12
        }
}
BACKGROUND Anagrelide is a cytoreductive agent used to lower platelet counts in essential thrombocythemia. Although the drug has been known to selectively inhibit megakaryopoiesis for many years, the molecular mechanism accounting for this activity is still unclear. OBJECTIVES AND METHODS To address this issue we have compared the global gene expression profiles of human hematopoietic cells treated ex-vivo with and without anagrelide while growing under megakaryocyte differentiation… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 55 REFERENCES